KEAP1

KEAP1 encodes a protein whose entire biological purpose is to say no. Under normal, unstressed conditions, KEAP1 continuously binds the transcription factor NRF2 and presents it to a Cullin3-based ubiquitin ligase complex, marking NRF2 for rapid proteasomal degradation. This keeps NRF2 protein levels, and the large program of antioxidant and detoxification genes it can activate, switched off until they are actually needed.

What makes KEAP1 unusual among negative regulators is that it functions as a direct chemical sensor rather than an enzyme responding to an upstream signaling cascade. KEAP1 contains an unusually high number of reactive cysteine residues, several of which are positioned to react directly with oxidants and electrophilic compounds. When these cysteines are chemically modified, KEAP1 undergoes a conformational change that disables its ability to deliver NRF2 for degradation, allowing NRF2 to accumulate, enter the nucleus, and activate its target genes.

Once stabilized, NRF2 partners with small MAF proteins and binds antioxidant response elements found in the promoters of several hundred genes, including those encoding glutathione synthesis enzymes, NAD(P)H quinone dehydrogenase, heme oxygenase 1, and numerous drug-metabolizing and efflux transporters. This coordinated transcriptional program is one of the most powerful cytoprotective responses available to a human cell, and KEAP1 is the switch that keeps it in reserve rather than constantly running.

This same switch becomes a liability when it breaks. Recurrent somatic loss-of-function mutations in KEAP1, found in a meaningful fraction of non-small-cell lung cancers, permanently disable NRF2 degradation. The resulting constitutively active NRF2 program protects tumor cells from oxidative damage and chemotherapy just as effectively as it would protect a healthy cell from environmental stress, making KEAP1 mutation status one of the more clinically important predictors of treatment resistance in lung cancer, and a clear illustration of how a single protective mechanism can be repurposed by disease.

Overview

KEAP1 encodes a protein whose entire biological purpose is to say no. Under normal, unstressed conditions, KEAP1 continuously binds the transcription factor NRF2 and presents it to a Cullin3-based ubiquitin ligase complex, marking NRF2 for rapid proteasomal degradation. This keeps NRF2 protein levels, and the large program of antioxidant and detoxification genes it can activate, switched off until they are actually needed.

What makes KEAP1 unusual among negative regulators is that it functions as a direct chemical sensor rather than an enzyme responding to an upstream signaling cascade. KEAP1 contains an unusually high number of reactive cysteine residues, several of which are positioned to react directly with oxidants and electrophilic compounds. When these cysteines are chemically modified, KEAP1 undergoes a conformational change that disables its ability to deliver NRF2 for degradation, allowing NRF2 to accumulate, enter the nucleus, and activate its target genes.

Once stabilized, NRF2 partners with small MAF proteins and binds antioxidant response elements found in the promoters of several hundred genes, including those encoding glutathione synthesis enzymes, NAD(P)H quinone dehydrogenase, heme oxygenase 1, and numerous drug-metabolizing and efflux transporters. This coordinated transcriptional program is one of the most powerful cytoprotective responses available to a human cell, and KEAP1 is the switch that keeps it in reserve rather than constantly running.

This same switch becomes a liability when it breaks. Recurrent somatic loss-of-function mutations in KEAP1, found in a meaningful fraction of non-small-cell lung cancers, permanently disable NRF2 degradation. The resulting constitutively active NRF2 program protects tumor cells from oxidative damage and chemotherapy just as effectively as it would protect a healthy cell from environmental stress, making KEAP1 mutation status one of the more clinically important predictors of treatment resistance in lung cancer, and a clear illustration of how a single protective mechanism can be repurposed by disease.

Deep Dive

Chemical Sensing: How a Protein Detects Stress Without a Receptor

Most stress-sensing pathways begin with a ligand binding a receptor. KEAP1 works differently: it senses stress through direct chemical reactivity of its own amino acid side chains.

• Reactive cysteines as built-in sensors. KEAP1 contains a notably high density of cysteine residues, several of which have unusually low pKa values that make them highly reactive toward oxidants and electrophiles.
• Modification, not new binding, drives the switch. Oxidation or covalent adduction of specific cysteines (well studied examples include those in the intervening region between KEAP1’s structural domains) triggers a conformational change rather than recruiting a new binding partner.
• A tunable, graded sensor. Because different inducers modify different subsets of KEAP1’s reactive cysteines with different efficiencies, the pathway can respond with graded, stimulus-specific intensity rather than a simple on-off switch.

The Ubiquitination Cycle: Continuous Degradation as a Default State

Understanding KEAP1 requires appreciating that NRF2 degradation is not a rare event triggered occasionally; it is the constant, ongoing default state of the cell.

• A dimeric adaptor with two-point substrate binding. KEAP1 functions as a homodimer, and this dimeric structure allows it to engage the two distinct binding motifs (a high-affinity and a low-affinity site) within NRF2’s Neh2 domain, a two-site “hinge and latch” mechanism that promotes efficient ubiquitination.
• NRF2 has an unusually short half-life under basal conditions. Continuous KEAP1-Cullin3-mediated ubiquitination keeps basal NRF2 protein turnover very rapid, meaning even brief disruption of this cycle can produce a relatively fast rise in NRF2 levels.
• Disabling the ligase, not just releasing the substrate. Some stress conditions impair the ubiquitination activity of the KEAP1-Cullin3 complex without immediately dissociating NRF2 from KEAP1, showing that pathway activation can occur through more than one biochemical route.

Non-Canonical Activation: The p62/SQSTM1 Connection

Not all NRF2 activation depends on cysteine chemistry. A second, autophagy-linked mechanism converges on the same outcome.

• p62 competes directly for the Kelch domain. The autophagy adaptor protein p62/SQSTM1 contains a KEAP1-interacting motif that structurally mimics part of NRF2’s own binding sequence, allowing p62 to compete for the same binding surface.
• Autophagy status becomes a redox signal. When autophagic flux is impaired, p62 accumulates and increasingly sequesters KEAP1, stabilizing NRF2 independent of any oxidative or electrophilic stress.
• A feed-forward loop. NRF2 itself can upregulate p62 transcription, creating a positive feedback loop that can reinforce and prolong NRF2 activation once initiated by either cysteine modification or autophagy impairment.

Pathogenic Loss-of-Function: Why Cancer Selects for Broken KEAP1

The same features that make KEAP1 an effective sensor also make it vulnerable to disease-relevant mutation.

• Loss-of-function mutations scattered across functional domains. Cancer-associated KEAP1 mutations occur throughout the BTB, intervening region, and Kelch domains, generally converging on impaired NRF2 binding or impaired Cullin3 engagement rather than one single hotspot.
• A selectable advantage for tumor cells. Because constitutively active NRF2 upregulates antioxidant, detoxification, and drug efflux genes, tumor cells with KEAP1 loss-of-function mutations gain a survival advantage under the oxidative and genotoxic stress imposed by chemotherapy and radiation.
• Co-occurrence with other oncogenic drivers. KEAP1 mutations frequently co-occur with KRAS or STK11 alterations in lung cancer, and this combination is associated with a particularly poor response to immune checkpoint inhibitors, an active area of clinical research.

Interpreting NRF2 Pathway Biomarkers

Because NRF2 protein itself is difficult to measure reliably in routine settings, pathway activity is generally inferred from its downstream targets.

• Target gene expression reflects net pathway activity, not KEAP1 status specifically. Elevated NQO1 or HMOX1 expression can result from KEAP1 mutation, p62 accumulation, or simple environmental oxidative exposure, so elevated markers alone cannot distinguish the underlying cause.
• Tumor genotyping is the most direct clinical tool available. In oncology, direct sequencing of KEAP1 and NFE2L2 in tumor tissue provides more actionable information than indirect pathway activity markers.
• Context determines whether pathway activation is desirable. The same NRF2 target gene signature that indicates helpful hormetic adaptation in a healthy tissue indicates a therapy-resistance mechanism in a KEAP1-mutant tumor, so interpretation always requires knowing the tissue and clinical context.